Plaque Psoriasis

Armstrong’s interview highlights oral therapies in the psoriasis treatment space highlighted in her session at the 2026 AAD meeting.

Armstrong highlights several major takeaways from her portion of the AAD 2026 session titled 'IL-23 Innovation: New Data Addressing Plaque Psoriasis.'

This Q&A interview from AAD 2026 covers a number of notable tips for clinicians in dermatology regarding topical therapies.

This review of dermatology news from the first quarter of 2026 highlights key headlines, FDA news, and more.

This summary of March 2026 highlights key news and developments in the dermatology news space.

This review of new data on psoriasis treatments from AAD 2026 highlights several key trials.

Check out exclusive expert interviews of late breaking data from AAD 2026.

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

The IMMpactful direct comparison provides prospective data in a moderate psoriasis population that previous MAICs could not fully capture.

These 52-week, phase 3 data on icotrokinra, presented at AAD, highlight the drug's efficacy and safety among adults with moderate to severe plaque psoriasis.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Soung discussed how new 52-week data support icotrokinra's recent FDA approval, marketed as Icotyde.

Tildrakizumab is US FDA-approved for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

These new data on spesolimab (Spevigo) in adults with generalized pustular psoriasis highlight long-term findings with the treatment.

Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.

In this Q&A, Linda Stein Gold, MD, shares her views on the clinical significance of icotrokinra's FDA approval and the data leading to this approval.

After the oral IL-23 inhibitor icotrokinra's (Icotyde) FDA approval, this interview covers what primary care clinicians should conclude.

Linda Stein Gold, MD, shares her perspective on the clinical significance of icotrokinra's FDA approval and what dermatologists need to know.

This preview highlights key data to watch out for during the 2026 American Academy of Dermatology (AAD) meeting in Denver, Colorado.

FDA clears once-daily icotrokinra for moderate-to-severe plaque psoriasis in adults and teens.

An audio recap of the top 5 stories in healthcare news from the week of 03/02-03/08.

This segment of Bhatia's interview highlights imsidolimab's reported durability of response for those with generalized pustular psoriasis (GPP).

This interview highlights the significance of the potential FDA approval of imsidolimab for patients with generalized pustular psoriasis (GPP).

This Q&A with Neal Bhatia, MD, features a discussion conducted regarding GLP-1 use in patients with psoriasis and obesity or overweight.

In this February review of the most significant developments in dermatology, the month’s most notable coverage of disease states such as psoriasis and atopic dermatitis is highlighted.